Central Hemodynamics and Drugs of Choice for the Correction of Hypertension in Chronic Kidney Disease

D.D. Ivanov

Abstract


The article presents the physiology, pathophysiology and practical aspects of the role and relationship of сentral blood pressure, augmentation index, vascular wall stiffness and arterial pressure at the shoulder. The role of pharmacological approach in lowering the сentral pressure and increasing the survival rate of patients with chronic kidney disease is shown.


Keywords


central blood pressure; augmentation index; arterial stiffness; central pulse pressure; cardiovascular mortality

References


Roman M.J., Devereux R.B., Kizer J.R., Lee E.T., Galloway J.M., Ali T., Umans J.G. and Howard B.V. Central Pressure More Strongly Relates to Vascular Disease and Outcome Than Does Brachial Pressure. The Strong Heart Study // Hypertension. — May 2007. — Р. HYPERTENSIONAHA.107.089078.

Roman M.J., Devereux R.B., Kizer J.R., Okin P.M., Lee E.T., Wang W., Umans J.G., Calhoun D. and Howard B.V. High Central Pulse Pressure Is Independently Associated With Adverse Cardiovascular Outcome: The Strong Heart Study // J. Am. Coll. Cardiol. — Vol. 54, Oct 2009. — P. 1730-1734.

Avolio A. Central Aortic Blood Pressure and Cardiovascular Risk: A Paradigm Shift? // Hypertension. — Jun 2008. — Vol. 51. — Р. 1470-1471.

McEniery C.M., Cockcroft J.R. et al. Central blood pressure: current evidence and clinical importance // Eur. Heart J. — 2014 Jul. —35(26). — 1719-25.

Carlberg B., Samuelsson O., Lindholm L.H. Atenolol in hypertension: is it a wise choice? // Lancet. — 2004. — 364. — 1684-1689.

Lindholm L.H., Carlberg B., Samuelsson O. Should beta blockers remain first choice in the treatment of primary hypertension? A Meta-Analysis // Lancet. — 2005. — 366. — 1545-1553.

Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party // BMJ. — 1992. — 304. — 405-412.

Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., Faire U., Fyhrquist F., Ibsen H., Kristiansson K., Lederballe-Peder­sen O., Lindholm L.H., Nieminen M.S., Omvik P., Oparil S., Wedel H. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol // Lancet. — 2002. — 359. — 995-1003.

Dahlof B., Sever P.S., Poulter N.R., Wedel H., Beevers D.G., Caulfield M., Collins R., Kjeldsen S.E., Kristinsson A., McInnes G.T., Mehlsen J., Nieminen M., O’Brien E., Ostergren J. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial // Lancet. — 2005. — 366. — 895-906.

Deary A.J., Schumann A.L., Murfet H., Haydock S., Foo R.S., Brown M.J. Influence of drugs and gender on the arterial pulse wave and natriuretic peptide secretion in untreated patients with essential hypertension // Clin. Sci. — 2002. — 103. — 493-499.

Dhakam Z., Yasmin, McEniery C.M., Burton T., Brown M.J., Wilkinson I.B. A comparison of atenolol and nebivolol in isolated systolic hypertension // J. Hypertens. — 2008. — 26. — 351-356.

Kampus P., Serg M., Kals J., Zagura M., Muda P., Karu K., Zilmer M., Eha J. Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness // Hypertension. — 2011. — 57. — 1122-1128.

Naidu M.U.R. Effect of beta-1-blocker, nebivolol, on central aortic pressure and arterial stiffness in patients with essential hypertension Indian // Journal of Pharmacology. — 2012. — Vol. 44, № 3. — 407-411.

Van de Borne at al. The Effect of Nebivolol and Atenolol on Renal and Systemic Haemodynamics in Hypertensive Patients // High Blood Pressure & Cardiovascular Prevention. — 2007. — 14, № 3. — 133-137.

Ptinopoulou A.G., Pikilidou M.I., Lasaridis A.N. The effect of antihypertensive drugs on chronic kidney disease: a comprehensive review // Hypertension Research. — 2013. — 36. — 2. — 91-101.

Wright R.S., Reeder G.S., Herzogetal C.A. Acutemyocardial infarction and renal dysfunction: a high-risk combination // Annals of Internal Medicine. — 2002. — 137. — 7. — 563-570.

Abbott K.C., Trespalacios F.C., Agodoa L.Y., Taylor A.J. β-blocker use in long-term dialysis patients: association with hospita­lized heart failure and mortality // Archives of Internal Medicine. — 2004. — 164. — 22. — 2465-2471.

Badve S.V., Roberts M.A. et al. Effects of beta-adrenergic antagonists in patients with chronic kidney disease:asystematic review and meta-analysis // Journal of the American College of Cardio­logy. — 2011. — 58. — 11. — 1152-1161.

Green D., Roberts P. R. et al. Sudden cardiac death in hemodialysis patients: an in-depth review // American Journal of Kidney Diseases. — 2011. — 57. — 6. — 921-929.

O’Rourke M.F., Safar M.E. Relationship between aortic stif­fening and microvascular disease in brain and kidney: cause and logic of therapy // Hypertension. — 2005. — 46. — 200-204.

Loutzenhiser R., Bidani A.K., Wang X. Systolic pressure and the myogenic response of the renal afferent arteriole // Acta Physiol. Scand. — 2004. — 181. — 407-413.

Bidani A.K., Griffin K.A., Williamson G., Wang X., Loutzenhiser R. Protective importance of the myogenic response in the renal circulation // Hypertension. — 2009. — 54. — 393-398.

Griffin K.A. Hypertension and kidney damage // J. Clin. Hypertens (Greenwich). — 2006. — 8. — 209-214.

Loutzenhiser R., Griffin K.A., Bidani A.K. Systolic blood pressure as the trigger for the renal myogenic response: protective or autoregulatory? // Curr. Opin. Nephrol. Hypertens. — 2006. — 15. — 41-49.

Bidani A.K., Polichnowski A.J., Loutzenhiser R., Griffin K.A. Renal microvascular dysfunction, hypertension and CKD progression // Curr. Opin. Nephrol. Hypertens. — 2013. — 22. — 1-9.

Hill G.S., Heudes D., Jacquot C., Gauthier E., Bariety J. Morphometric evidence for impairment of renal autoregulation in advanced essential hypertension // Kidney Int. — 2006. — 69. — 823-831.

Michel E. Safar, Jacques Blacher et al. Central Pulse Pressure and Mortality in End-Stage Renal Disease // Hypertension. — 2002. — 39. — 735-738.

Bogren H.G., Buonocore M.H. Blood flow measurements in the aorta and major arteries with MR velocity mapping // J. Magn. Reson. Imaging. — 1994. — 4. — 119-130.

Chirinos. J.A. et al. Aortic Pressure Augmentation Predicts Adverse Cardiovascular Events in Patients With Established Coronary Artery Disease // Hypertension. — 2005. — 45. — 980-985.

Carlberg B. et al. Atenolol in hypertension: is it a wise choice? // Lancet. — 2004, Nov 6–12. — 364(9446). — 1684-9.




DOI: https://doi.org/10.22141/2307-1257.0.1.15.2016.71468

Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 KIDNEYS

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru